NASDAQ:CARA - Cara Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.80
  • Forecasted Upside: 208.76 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.68
▲ +0.15 (1.76%)

This chart shows the closing price for CARA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CARA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CARA

Analyst Price Target is $26.80
▲ +208.76% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $26.80, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 208.76% upside from the last price of $8.68.

This chart shows the closing price for CARA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Cara Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2022Canaccord Genuity GroupLower Price Target$33.00 ➝ $29.00High
3/14/2022HC WainwrightLower Price TargetBuy$35.00 ➝ $30.00Low
3/14/2022Canaccord Genuity GroupLower Price TargetBuy$33.00 ➝ $29.00Low
3/8/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$17.00 ➝ $20.00High
8/24/2021Needham & Company LLCInitiated CoverageBuy$26.00High
8/24/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $35.00High
8/10/2021Needham & Company LLCInitiated CoverageBuy$26.00High
8/3/2021JPMorgan Chase & Co.Initiated CoverageNeutral$16.00High
4/29/2021Needham & Company LLCLower Price TargetBuy$35.00 ➝ $26.00High
4/15/2021Needham & Company LLCReiterated RatingBuy$35.00Low
8/11/2020Needham & Company LLCReiterated RatingBuy$35.00Low
6/18/2020Needham & Company LLCReiterated RatingBuy$35.00Medium
5/19/2020Cantor FitzgeraldBoost Price TargetOverweight$34.00 ➝ $40.00Low
4/22/2020Cantor FitzgeraldBoost Price TargetOverweight$26.00 ➝ $34.00Medium
4/21/2020Needham & Company LLCInitiated CoverageBuy$35.00Low
4/21/2020HC WainwrightBoost Price TargetPositive ➝ Buy$30.00 ➝ $33.00High
12/4/2019Cantor FitzgeraldBoost Price Target$29.00 ➝ $33.00High
12/3/2019Needham & Company LLCReiterated RatingBuy$35.00High
12/3/2019HC WainwrightReiterated RatingBuy$30.00High
10/17/2019Needham & Company LLCReiterated RatingBuy$35.00Low
8/12/2019HC WainwrightReiterated RatingBuy ➝ Buy$31.00 ➝ $30.00Low
7/30/2019Piper Jaffray CompaniesBoost Price TargetOverweight$35.00 ➝ $39.00Medium
7/22/2019HC WainwrightBoost Price TargetBuy ➝ Average$28.00 ➝ $31.00Low
5/29/2019LaidlawBoost Price TargetBuy$26.00 ➝ $32.00Low
5/29/2019HC WainwrightBoost Price TargetBuy$26.00 ➝ $28.00High
5/29/2019Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $35.00High
2/6/2019Jefferies Financial GroupInitiated CoverageBuy$22.00Low
1/15/2019Bank of AmericaInitiated CoverageNeutral$19.00Low
12/20/2018HC WainwrightSet Price TargetBuy$30.00Low
12/20/2018LaidlawSet Price TargetBuy$30.00Low
12/20/2018Piper Jaffray CompaniesSet Price TargetBuy$27.00Low
12/20/2018Janney Montgomery ScottInitiated CoverageBuy$27.00 ➝ $13.36High
11/7/2018Cantor FitzgeraldSet Price TargetBuy$27.00High
10/4/2018Cantor FitzgeraldReiterated RatingBuy$27.00High
9/21/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$27.00High
9/13/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$30.00High
8/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.00High
8/8/2018HC WainwrightSet Price TargetBuy$26.00High
6/28/2018HC WainwrightBoost Price TargetPositive ➝ Buy$24.00 ➝ $26.00High
6/27/2018Needham & Company LLCBoost Price TargetPositive ➝ Buy$23.00 ➝ $28.00High
5/24/2018LaidlawSet Price TargetBuy$26.00Low
5/23/2018HC WainwrightBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.00High
5/23/2018Stifel NicolausBoost Price TargetBuy$20.00High
5/11/2018HC WainwrightSet Price TargetBuy$22.00Low
3/19/2018HC WainwrightSet Price TargetBuy$22.00High
3/12/2018HC WainwrightReiterated RatingBuy$22.00Low
2/12/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$27.00 ➝ $21.00High
1/3/2018Stifel NicolausReiterated RatingBuy$17.00High
11/7/2017Raymond JamesBoost Price TargetMarket Perform$25.00 ➝ $26.00N/A
11/7/2017CIBCLower Price Target$26.00 ➝ $24.00N/A
11/7/2017BMO Capital MarketsReiterated RatingMarket Perform$25.00N/A
10/17/2017ScotiabankBoost Price TargetOutperform$31.00 ➝ $31.50N/A
10/4/2017Needham & Company LLCReiterated RatingBuy$23.00Low
9/28/2017ScotiabankLower Price TargetOutperform$32.00 ➝ $31.00Medium
8/5/2017Piper Jaffray CompaniesSet Price TargetBuy$27.00High
8/4/2017HC WainwrightReiterated RatingBuy$30.00High
8/3/2017ScotiabankLower Price TargetOutperform$34.00 ➝ $32.00Low
8/3/2017Royal Bank of CanadaLower Price TargetOutperform$31.00 ➝ $29.00Low
8/3/2017Raymond JamesLower Price TargetMarket Perform$28.00 ➝ $25.00Low
7/1/2017Piper Jaffray CompaniesReiterated RatingBuy$27.00High
6/30/2017Needham & Company LLCReiterated RatingBuy$23.00Low
6/30/2017HC WainwrightReiterated RatingBuy$30.00Low
6/30/2017LaidlawLower Price TargetBuy$35.00 ➝ $30.00High
6/30/2017Stifel NicolausReiterated RatingBuy ➝ Buy$24.00 ➝ $20.00High
6/30/2017Janney Montgomery ScottDowngradeBuy ➝ Neutral$22.00 ➝ $21.00High
6/28/2017Janney Montgomery ScottReiterated RatingBuy ➝ Buy$22.00High
6/23/2017Stifel NicolausReiterated RatingBuy$24.00 ➝ $20.00High
6/22/2017HC WainwrightReiterated RatingBuy$30.00High
6/21/2017Needham & Company LLCReiterated RatingBuy$23.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/21/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
3/23/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/22/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Cara Therapeutics logo
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Read More

Today's Range

Now: $8.68
Low: $8.37
High: $8.91

50 Day Range

MA: $11.14
Low: $7.45
High: $13.84

52 Week Range

Now: $8.68
Low: $7.40
High: $18.93

Volume

512,862 shs

Average Volume

951,745 shs

Market Capitalization

$465.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Cara Therapeutics?

The following Wall Street research analysts have issued stock ratings on Cara Therapeutics in the last year: Canaccord Genuity Group Inc., HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CARA.

What is the current price target for Cara Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cara Therapeutics in the last year. Their average twelve-month price target is $26.80, suggesting a possible upside of 208.8%.
View the latest price targets for CARA.

What is the current consensus analyst rating for Cara Therapeutics?

Cara Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CARA will outperform the market and that investors should add to their positions of Cara Therapeutics.
View the latest ratings for CARA.

How do I contact Cara Therapeutics' investor relations team?

Cara Therapeutics' physical mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company's listed phone number is (203) 406-3700 and its investor relations email address is [email protected] The official website for Cara Therapeutics is www.caratherapeutics.com. Learn More about contacing Cara Therapeutics investor relations.